Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30

$6.96−0.22 (-3.06%)

Close on Nov 13, 2026Market cap $459.71MP/E –Yield –

Evolus operating margin

Operating margin is operating income as a percentage of revenue.

Evolus's operating margin for the twelve months ending Sep 30, 2026 was -4.8%. For fiscal 2025 it was -11.0%, against -12.9% the year before. The highest annual figure on record is -11.0% in fiscal 2025.

Annual operating margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-11.0%	+1.9
FY2024	Dec 31, 2024	-12.9%	+11.4
FY2023	Dec 31, 2023	-24.4%	+19.6
FY2022	Dec 31, 2022	-44.0%	+0.6
FY2021	Dec 31, 2021	-44.6%	+226.2
FY2020	Dec 31, 2020	-270.7%	+12.6
FY2019	Dec 31, 2019	-283.3%	–

Quarterly operating margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-10.8%	+5.9
Q2 FY2026	Jun 30, 2026	-5.4%	+9.3
Q1 FY2026	Mar 31, 2026	-9.4%	+12.8
Q4 FY2025	Dec 31, 2025	4.7%	+7.6
Q3 FY2025	Sep 30, 2025	-16.7%	+8.7
Q2 FY2025	Jun 30, 2025	-14.7%	−3.2
Q1 FY2025	Mar 31, 2025	-22.1%	−7.1
Q4 FY2024	Dec 31, 2024	-2.9%	+11.2
Q3 FY2024	Sep 30, 2024	-25.3%	+1.5
Q2 FY2024	Jun 30, 2024	-11.5%	+19.1
Q1 FY2024	Mar 31, 2024	-15.0%	+13.8
Q4 FY2023	Dec 31, 2023	-14.2%	+10.2
Q3 FY2023	Sep 30, 2023	-26.9%	+25.9
Q2 FY2023	Jun 30, 2023	-30.6%	+26.8
Q1 FY2023	Mar 31, 2023	-28.9%	+16.7
Q4 FY2022	Dec 31, 2022	-24.4%	+27.6
Q3 FY2022	Sep 30, 2022	-52.8%	+18.8
Q2 FY2022	Jun 30, 2022	-57.4%	+1.2
Q1 FY2022	Mar 31, 2022	-45.6%	−111.1
Q4 FY2021	Dec 31, 2021	-52.0%	+473.0
Q3 FY2021	Sep 30, 2021	-71.6%	−22.0
Q2 FY2021	Jun 30, 2021	-58.6%	+183.4
Q1 FY2021	Mar 31, 2021	65.6%	+231.3
Q4 FY2020	Dec 31, 2020	-525.0%	−460.5
Q3 FY2020	Sep 30, 2020	-49.6%	+141.3
Q2 FY2020	Jun 30, 2020	-242.0%	+1315.7
Q1 FY2020	Mar 31, 2020	-165.7%	–
Q4 FY2019	Dec 31, 2019	-64.5%	–
Q3 FY2019	Sep 30, 2019	-190.9%	–
Q2 FY2019	Jun 30, 2019	-1557.6%	–